KRAS and familial pancreatic carcinoma: In a clinical study, the G12D mutation was noted to be the most prevalent KRAS mutant transgressor amongst pancreatic cancer patients, comprising 44.9% (115/256), and CRC patients, comprising 30.8% (45/146).